Krishna B Singh
Overview
Explore the profile of Krishna B Singh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
259
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luke J, Dadey R, Augustin R, Newman S, Singh K, Doerfler R, et al.
Res Sq
. 2023 Aug;
PMID: 37645831
Patients with tumors that do not respond to immune-checkpoint inhibition often harbor a non-T cell-inflamed tumor microenvironment, characterized by the absence of IFN-γ-associated CD8 T cell and dendritic cell activation....
2.
Singh K, Hahm E, Kim S, Singh S
Cancer Prev Res (Phila)
. 2022 Oct;
16(1):5-16.
PMID: 36251722
Prevention Relevance: The present study shows that breast cancer prevention by WA in rats is associated with suppression of fatty acid synthesis.
3.
Singh K, Hahm E, Singh S
J Cancer Metastasis Treat
. 2021 Oct;
7.
PMID: 34660908
Aim: Leelamine (LLM) inhibits growth of human prostate cancer cells but the underlying mechanism is not fully understood. The present study was undertaken to determine the effect of LLM on...
4.
Kim S, Singh K, Hahm E, Singh S
Cancer Prev Res (Phila)
. 2021 Jan;
14(4):421-432.
PMID: 33509807
Elimination of both rapidly dividing epithelial mammary cancer cells as well as breast cancer stem-like cells (bCSC) is essential for maximizing antitumor response. Withaferin A (WA), a small molecule derived...
5.
Singh K, Hahm E, Kim S, Wendell S, Singh S
Oncogene
. 2020 Nov;
40(3):592-602.
PMID: 33199826
A subset of human prostate cancer exhibits increased de novo synthesis of fatty acids, but the molecular driver(s) of this metabolic abnormality remains obscure. This study demonstrates a novel metabolic...
6.
Hahm E, Kim S, Singh K, Singh S
Mol Carcinog
. 2020 Nov;
60(1):3-14.
PMID: 33150660
Withaferin A (WA) exhibits cancer chemopreventive efficacy in preclinical models representative of two different subtypes of breast cancer. However, the mechanism(s) underlying breast cancer chemoprevention by WA is not fully...
7.
Kim S, Hahm E, Singh K, Singh S
Mol Carcinog
. 2020 Aug;
59(10):1116-1128.
PMID: 32754922
The transcription factor forkhead box Q1 (FoxQ1) is overexpressed in different solid tumors including breast cancer, but the mechanism underlying its oncogenic function is still not fully understood. In this...
8.
Hahm E, Kim S, Singh K, Singh K, Singh S
Cancer Prev Res (Phila)
. 2020 Jul;
13(9):721-734.
PMID: 32727824
Withaferin A (hereafter abbreviated as WA) is a promising anticancer steroidal lactone abundant in a medicinal plant () native to Asia. The root/leaf extract of , which belongs to the...
9.
Kim S, Singh K, Hahm E, Lokeshwar B, Singh S
J Tradit Complement Med
. 2020 Jul;
10(3):188-197.
PMID: 32670813
Prior research argues for a role of increased fatty acid synthesis in pathogenesis of prostate adenocarcinoma, which remains a leading cause of cancer-associated mortality in American men. A safe and...
10.
Hahm E, Singh K, Kim S, Powolny A, Singh S
Cancer Prev Res (Phila)
. 2020 May;
13(8):661-672.
PMID: 32434809
Prostate cancer chemoprevention by sulforaphane, which is a metabolic by-product of glucoraphanin found in broccoli, in preclinical models is associated with induction of both apoptosis and autophagy. However, the molecular...